Quote:
|
Originally Posted by Furious_Male
Elan was counting on one multiple sclerosis drug that didnt pan out. If I am not mistaken if you check the charts further back you will see the spike when the drug showed promise.
They are back down to where they belong.
|
BIIB who was also affected by this seems like a good buy right now below $40, but I'm keeping my goal to not touch drug companies